Cargando…

Netupitant PET imaging and ADME studies in humans

Netupitant is a new, selective NK(1) receptor antagonist under development for the prevention of chemotherapy-induced nausea and vomiting. Two studies were conducted to evaluate the brain receptor occupancy (RO) and disposition (ADME) of netupitant in humans. Positron emission tomography (PET) imagi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spinelli, Tulla, Calcagnile, Selma, Giuliano, Claudio, Rossi, Giorgia, Lanzarotti, Corinna, Mair, Stuart, Stevens, Lloyd, Nisbet, Ian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282341/ https://www.ncbi.nlm.nih.gov/pubmed/24122871 http://dx.doi.org/10.1002/jcph.198

Ejemplares similares

Drug–drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data
por: Natale, James J, et al.
Publicado: (2015)

Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial
por: Spinelli, Tulla, et al.
Publicado: (2014)

Profile of Antiemetic Activity of Netupitant Alone or in Combination with Palonosetron and Dexamethasone in Ferrets and Suncus murinus (House Musk Shrew)
por: Rudd, John A., et al.
Publicado: (2016)

Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3‐day aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study
por: Chang, Jianhua, et al.
Publicado: (2020)

Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
por: Shirley, Matt
Publicado: (2021)

Correction to: Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
por: Shirley, Matt
Publicado: (2021)

Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetron
por: Lorusso, Vito
Publicado: (2016)

A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)
por: Zhang, L, et al.
Publicado: (2018)

Netupitant and palonosetron trigger NK(1) receptor internalization in NG108-15 cells
por: Thomas, Ajit G., et al.
Publicado: (2014)

Management of acute and delayed chemotherapy-induced nausea and vomiting: role of netupitant–palonosetron combination
por: Janicki, Piotr K
Publicado: (2016)

ADME-Space: a new tool for medicinal chemists to explore ADME properties
por: Bocci, Giovanni, et al.
Publicado: (2017)

The First Oral Fixed-Dose Combination of Netupitant and Palonosetron for the Treatment of Chemotherapy-Induced Nausea and Vomiting
por: Coyne, Joseph W.
Publicado: (2016)

Management of Chemotherapy-Induced Nausea and Vomiting (CINV): A Short Review on the Role of Netupitant-Palonosetron (NEPA)
por: Lorusso, Vito, et al.
Publicado: (2020)

Simulation of the oxidative metabolization pattern of netupitant, an NK(1) receptor antagonist, by electrochemistry coupled to mass spectrometry
por: Chira, Ruxandra, et al.
Publicado: (2021)

Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice
por: Aapro, Matti, et al.
Publicado: (2022)

Altered expression of ADM and ADM2 by hypoxia regulates migration of trophoblast and HLA-G expression
por: Gu, Changdai, et al.
Publicado: (2020)

Matrine reverses the drug resistance of K562/ADM cells to ADM and VCR via promoting autophagy
por: Li, Zhao, et al.
Publicado: (2020)

An in vitro ADME and in vivo Pharmacokinetic Study of Novel TB-Active Decoquinate Derivatives
por: Tanner, Lloyd, et al.
Publicado: (2019)

Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV)
por: Baron-Hay, Sally, et al.
Publicado: (2019)

An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data
por: James, Alexander D., et al.
Publicado: (2020)

Netupitant, a Potent and Highly Selective NK(1) Receptor Antagonist, Alleviates Acetic Acid-Induced Bladder Overactivity in Anesthetized Guinea-Pigs
por: Palea, Stefano, et al.
Publicado: (2016)

Duality, Entropy and ADM Mass in Supergravity
por: Cerchiai, Bianca L., et al.
Publicado: (2009)

Fixed combination of oral NEPA (netupitant‐palonosetron) for the prevention of acute and delayed chemotherapy‐induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double‐blind phase III studies
por: Schwartzberg, Lee, et al.
Publicado: (2019)

Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective
por: Nilsson, Jonas, et al.
Publicado: (2022)

Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development
por: Tibbitts, Jay, et al.
Publicado: (2015)

Anti-emetic Action of the Brain-Penetrating New Ghrelin Agonist, HM01, Alone and in Combination With the 5-HT(3) Antagonist, Palonosetron and With the NK(1) Antagonist, Netupitant, Against Cisplatin- and Motion-Induced Emesis in Suncus murinus (House Musk Shrew)
por: Rudd, John A., et al.
Publicado: (2018)

Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)
por: Navari, Rudolph M
Publicado: (2014)

Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic
por: Hesketh, Paul J., et al.
Publicado: (2017)

Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy‐Induced Nausea and Vomiting
por: Gilmore, James, et al.
Publicado: (2018)

Corrigendum: Anti-emetic Action of the Brain-Penetrating New Ghrelin Agonist, HM01, Alone and in Combination With the 5-HT(3) Antagonist, Palonosetron and With the NK(1) Antagonist, Netupitant, Against Cisplatin- and Motion-Induced Emesis in Suncus murinus (House Musk Shrew)
por: Rudd, John A., et al.
Publicado: (2018)

To ADM or not to ADM? Outcomes of Pre-pectoral Prosthetic Reconstruction after Nipple-Sparing Mastectomy with and without Acellular Dermal Matrix
por: Bushong, E., et al.
Publicado: (2023)

Orthogonal Procrustes Analysis for Dictionary Learning in Sparse Linear Representation
por: Grossi, Giuliano, et al.
Publicado: (2017)

ADM masses for black strings and p-branes
por: Lu, J.X.
Publicado: (1993)

Dexamethasone‐Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High‐Dose Cisplatin: A Randomized Noninferiority Study
por: Celio, Luigi, et al.
Publicado: (2021)

NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron
por: Aapro, Matti, et al.
Publicado: (2016)

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
por: Hesketh, P. J., et al.
Publicado: (2014)

NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK
por: Cawston, Helene, et al.
Publicado: (2017)

The Expression Profiles of ADME Genes in Human Cancers and Their Associations with Clinical Outcomes
por: Hu, Dong Gui, et al.
Publicado: (2020)

Alcohol ADME in Primates Studied with Positron Emission Tomography
por: Li, Zizhong, et al.
Publicado: (2012)

The use of quantum chemistry in the prediction of ADME-Tox properties
por: Van Damme, S, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_m7haevd9g3qunachodcfmo44uo